DMRA Earnings Date: Nov 5, 2026 (Estimated) — Damora Therapeutics, Inc.

NASDAQ

Updated

Price $21.50
Market Cap $1.3B
P/E -0.2
52W Range $4.95 – $38.33
Next Earnings · After close (est.)

When is DMRA's next earnings date?

Damora Therapeutics, Inc. (DMRA) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.48.

How did DMRA do in its last earnings report?

In its most recent report on Aug 11, 2026, Damora Therapeutics, Inc. posted EPS of -$0.39 versus the -$0.41 estimate, a beat of 5.8%. The stock's 1-day post-earnings move was +4.9%.

How much does DMRA stock move after earnings?

DMRA beat EPS estimates in 3 of its last 5 reported quarters. Over the last 4 reports the stock moved an average of 4.5% (up or down) in the day after earnings.

About Damora Therapeutics, Inc.

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Earnings History

DatePeriodEPS Est.EPS Act.SurpriseRevenueResult1D Δ1W Δ1M Δ
2026-08-11-0.41-0.39+5.80%—✅ Beat+4.94%+5.25%-11.07%
2026-08-10Q2 2026-0.37-0.39-5.41%$0❌ Miss+2.78%+5.25%-11.07%
2026-05-12Q1 2026-0.56-0.62-10.71%$0❌ Miss+4.63%+4.11%-7.49%
2026-03-19Q4 2025-0.122.90+2516.67%$0✅ Beat-5.52%+33.49%+37.66%
2022-02-18-14.00-13.25——✅ Beat———

Showing last 5 quarters.

Learn More

Explore More

Financial data from licensed market-data providers; risk factors from SEC EDGAR filings. AI-powered analysis. Data last updated .